젠코어 (XNCR) 주가

젠코어(XNCR)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $24.72 (+0.53%), 시가총액 $0.94B, 52주 최저~최고 $7.00 ~ $18.14.

Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It also develops XmAb819, a bispecific antibody to treat renal cell carcinoma; XmAb541, which is in Phase I for the treatment of ovarian cancer; XmAb808, a bispecific antibody that binds to the broadly expressed tumor antigen; XmAb942, which is in clinica

핵심 지표

• 현재가: $24.72 (+0.53%)
• 시가총액: $0.94B
• 52주 최저~최고: $7.00 ~ $18.14
• 섹터: Healthcare
• 산업: Biotechnology
• 거래소: NASDAQ

젠코어의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.

젠코어 재무 요약

애널리스트 전망

• 투자의견 컨센서스: 4.5

핵심 재무비율 · 수익성 · 성장성

• PBR (주가순자산비율): 1.45
• 순이익률: -0.73%
• 영업이익률: -1.90%

자주 묻는 질문